VERTEX PHARMACEUTICALS INC / MA Direct Operating Cost, Royalty Expense (Deprecated 2018-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Direct Operating Cost, Royalty Expense (Deprecated 2018-01-31) of $340.00 thousand for the 3-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DirectOperatingCostRoyaltyExpense · last filed 2018-02-15
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $340.00K, a 59.33% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $688.00K, a 19.53% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $670.00K, a 38.98% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $746.00K, a 13.26% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for fiscal 2017 was $2.44M, a 33.02% decline from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for fiscal 2016 was $3.65M, a 50.43% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for fiscal 2015 was $7.36M, a 65.38% decline from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA direct operating cost, royalty expense (deprecated 2018-01-31) for fiscal 2014 was $21.26M, a 48.52% decline from fiscal 2013.
| Period end | Direct Operating Cost, Royalty Expense (Deprecated 2018-01-31) 3 month | Direct Operating Cost, Royalty Expense (Deprecated 2018-01-31) 6 month | Direct Operating Cost, Royalty Expense (Deprecated 2018-01-31) 9 month | Direct Operating Cost, Royalty Expense (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $340.00K 10-K · filed 2018-02-15 | $1.03M derived: sum of 2 quarters · filed 2018-02-15 | $1.70M derived: sum of 3 quarters · filed 2018-02-15 | $2.44M 10-K · filed 2018-02-15 |
| 2017-09-30 | $688.00K 10-K · filed 2018-02-15 | $1.36M derived: sum of 2 quarters · filed 2018-02-15 | $2.10M 10-Q · filed 2017-10-30 | $2.94M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | $670.00K 10-K · filed 2018-02-15 | $1.42M 10-Q · filed 2017-07-28 | $2.25M derived: sum of 3 quarters · filed 2018-02-15 | $3.11M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | $746.00K 10-K · filed 2018-02-15 | $1.58M derived: sum of 2 quarters · filed 2018-02-15 | $2.44M derived: sum of 3 quarters · filed 2018-02-15 | $3.54M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | $836.00K 10-K · filed 2018-02-15 | $1.69M derived: sum of 2 quarters · filed 2018-02-15 | $2.79M derived: sum of 3 quarters · filed 2018-02-15 | $3.65M 10-K · filed 2018-02-15 |
| 2016-09-30 | $855.00K 10-K · filed 2018-02-15 | $1.95M derived: sum of 2 quarters · filed 2018-02-15 | $2.81M 10-Q · filed 2017-10-30 | $4.11M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $1.10M 10-K · filed 2018-02-15 | $1.96M 10-Q · filed 2017-07-28 | $3.25M derived: sum of 3 quarters · filed 2018-02-15 | $4.94M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $860.00K 10-K · filed 2018-02-15 | $2.15M derived: sum of 2 quarters · filed 2018-02-15 | $3.84M derived: sum of 3 quarters · filed 2018-02-15 | $5.29M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $1.29M 10-K · filed 2017-02-23 | $2.98M derived: sum of 2 quarters · filed 2017-02-23 | $4.43M derived: sum of 3 quarters · filed 2017-02-23 | $7.36M 10-K · filed 2018-02-15 |
| 2015-09-30 | $1.69M 10-K · filed 2017-02-23 | $3.14M derived: sum of 2 quarters · filed 2017-02-23 | $6.07M 10-Q · filed 2016-10-31 | $8.80M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $1.45M 10-K · filed 2017-02-23 | $4.38M 10-Q · filed 2016-08-01 | $7.11M derived: sum of 3 quarters · filed 2017-02-23 | $11.09M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $2.93M 10-K · filed 2017-02-23 | $5.66M derived: sum of 2 quarters · filed 2017-02-23 | $9.64M derived: sum of 3 quarters · filed 2017-02-23 | $17.28M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $2.74M 10-K · filed 2016-02-16 | $6.71M derived: sum of 2 quarters · filed 2016-02-16 | $14.36M derived: sum of 3 quarters · filed 2016-02-16 | $21.26M 10-K · filed 2017-02-23 |
| 2014-09-30 | $3.98M 10-K · filed 2016-02-16 | $11.62M derived: sum of 2 quarters · filed 2016-02-16 | $18.52M 10-Q · filed 2015-10-30 | $27.51M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | $7.64M 10-K · filed 2016-02-16 | $14.55M 10-Q · filed 2015-08-04 | $23.53M derived: sum of 3 quarters · filed 2016-02-16 | $30.82M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | $6.90M 10-K · filed 2016-02-16 | $15.89M derived: sum of 2 quarters · filed 2016-02-16 | $23.18M derived: sum of 3 quarters · filed 2016-02-16 | $36.41M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | $8.98M 10-K · filed 2015-02-13 | $16.27M derived: sum of 2 quarters · filed 2015-02-13 | $29.51M derived: sum of 3 quarters · filed 2015-02-13 | $41.30M 10-K · filed 2016-02-16 |
| 2013-09-30 | $7.29M 10-K · filed 2015-02-13 | $20.53M derived: sum of 2 quarters · filed 2015-02-13 | $32.31M 10-Q · filed 2014-11-06 | $44.44M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $13.24M 10-K · filed 2015-02-13 | $25.02M 10-Q · filed 2014-07-31 | $37.14M derived: sum of 3 quarters · filed 2015-02-13 | $45.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $11.79M 10-K · filed 2015-02-13 | $23.91M derived: sum of 2 quarters · filed 2015-02-13 | $31.76M derived: sum of 3 quarters · filed 2015-02-13 | $41.64M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $12.12M 10-K · filed 2014-02-11 | $19.98M derived: sum of 2 quarters · filed 2014-02-11 | $29.85M derived: sum of 3 quarters · filed 2014-02-11 | $43.14M 10-K · filed 2015-02-13 |
| 2012-09-30 | $7.86M 10-K · filed 2014-02-11 | $17.73M derived: sum of 2 quarters · filed 2014-02-11 | $31.02M 10-Q · filed 2013-11-07 | $38.21M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $9.87M 10-K · filed 2014-02-11 | $23.17M 10-Q · filed 2013-08-02 | $30.36M derived: sum of 3 quarters · filed 2014-02-11 | $33.48M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $13.29M 10-K · filed 2014-02-11 | $20.48M derived: sum of 2 quarters · filed 2014-02-11 | $23.61M derived: sum of 3 quarters · filed 2014-02-11 | $27.51M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $7.19M 10-K · filed 2013-03-01 | $10.31M derived: sum of 2 quarters · filed 2013-03-01 | $14.21M derived: sum of 3 quarters · filed 2013-03-01 | $16.88M 10-K · filed 2014-02-11 |
| 2011-09-30 | $3.12M 10-K · filed 2013-03-01 | $7.02M derived: sum of 2 quarters · filed 2013-03-01 | $9.69M 10-Q · filed 2012-11-06 | $12.74M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $3.90M 10-K · filed 2013-03-01 | $6.57M 10-Q · filed 2012-08-08 | $9.62M derived: sum of 3 quarters · filed 2013-03-01 | $12.85M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $2.67M 10-K · filed 2013-03-01 | $5.71M derived: sum of 2 quarters · filed 2013-03-01 | $8.94M derived: sum of 3 quarters · filed 2013-03-01 | $12.03M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $3.05M 10-K · filed 2012-02-22 | $6.28M derived: sum of 2 quarters · filed 2012-02-22 | $9.36M derived: sum of 3 quarters · filed 2012-02-22 | $12.73M 10-K · filed 2013-03-01 |
| 2010-09-30 | $3.23M 10-K · filed 2012-02-22 | $6.31M derived: sum of 2 quarters · filed 2012-02-22 | $9.68M 10-Q · filed 2011-11-03 | $13.33M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $3.09M 10-K · filed 2012-02-22 | $6.45M 10-Q · filed 2011-08-09 | $10.10M derived: sum of 3 quarters · filed 2012-02-22 | $13.81M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | $3.37M 10-K · filed 2012-02-22 | $7.01M derived: sum of 2 quarters · filed 2012-02-22 | $10.73M derived: sum of 3 quarters · filed 2012-02-22 | $13.99M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | $3.65M 10-K · filed 2011-02-17 | $7.36M derived: sum of 2 quarters · filed 2011-02-17 | $10.63M derived: sum of 3 quarters · filed 2011-02-17 | $14.20M 10-K · filed 2012-02-22 |
| 2009-09-30 | $3.71M 10-K · filed 2011-02-17 | $6.98M derived: sum of 2 quarters · filed 2011-02-17 | $10.55M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $3.27M 10-K · filed 2011-02-17 | $6.84M 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | $3.58M 10-K · filed 2011-02-17 | |||
| 2008-12-31 | $15.69M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |